A switch in the direction of the effect of insulin on the partitioning of hepatic fatty acids for the formation of secreted triacylglycerol occurs in vivo, as predicted from studies with perfused livers.
The direct effects of insulin on hepatic triacylglycerol secretion are important because they may determine the degree of postprandial hyperlipidaemia, a known risk factor for the development of atherosclerotic lesions. Previous work from this laboratory, conducted on isolated perfused rat livers [Zammit, V.A., Lankester, D.J., Brown, A.M. & Park, B.S. (1999) Eur. J. Biochem. 263, 859-864], has indicated that the effect of insulin on hepatic triacylglycerol secretion is dependent on the prior physiological state of the donor animals. In this paper, we demonstrate that a switch in the direction of insulin action on hepatic partitioning of fatty acyl moieties towards triacylglycerol secretion also occurs in vivo between the fed, normoinsulinaemic state and the fasted or severely insulin-deficient states. The partitioning of fatty acids in the liver of awake, unstressed rats was studied using selective labelling of hepatic fatty acids during hyperinsulinaemic-euglycaemic clamps achieved through the use of hepatocyte-targeted liposome-encapsulated insulin preparations. The data show that, whereas in the fed, normoinsulinaemic state, insulinization of the liver raises the proportion of fatty acids directed towards secreted triacylglycerol, in the fasted or insulin-deficient states, insulin inhibits the partitioning of acyl moieties into secreted triacylglycerol. These data show that observations on the direction of insulin action on hepatic triacylglycerol secretion obtained using isolated perfused rat livers are reflected in the effects of the hormone on hepatic fatty acid partitioning in vivo. They offer an explanation for the positive relationship between chronic hyperinsulinaemia, hepatic VLDL-triacylglycerol secretion and hypertriglyceridaemia observed previously in insulin-resistant states.
Rennie
S M
SM
Cellular Biochemistry, Hannah Research Institute, Ayr, Scotland, UK.
Park
B S
BS
Zammit
V A
VA
D000818:Animals; D002908:Chronic Disease; D004337:Drug Carriers; D005215:Fasting / Q000097:blood; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood / Q000378:metabolism; D015228:Hypertriglyceridemia / Q000097:blood / Q000378:metabolism; D007328:Insulin / Q000008:administration & dosage / Q000097:blood / Q000172:deficiency / Q000494:pharmacology*; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008081:Liposomes; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*; D010477:Perfusion; D051381:Rats; D017208:Rats, Wistar; D015203:Reproducibility of Results; D014280:Triglycerides / Q000378:metabolism*
D004337:Drug Carriers; D005227:Fatty Acids; D007328:Insulin; D008079:Lipoproteins, VLDL; D008081:Liposomes; D014280:Triglycerides